Measles, mumps and rubella vaccine - Cadila Healthcare

Drug Profile

Measles, mumps and rubella vaccine - Cadila Healthcare

Alternative Names: MMR vaccine - Cadila Healthcare

Latest Information Update: 19 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cadila Healthcare
  • Class Measles vaccines; Rubella vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Measles; Mumps; Rubella

Most Recent Events

  • 11 Apr 2016 Cadila Healthcare completes a phase III trial for Measles, Mumps and Rubella (In infants, Prevention) in India (SC) before April 2016 (CTRI/2015/05/005784)
  • 31 Jan 2014 Phase-II clinical trials in Measles (prevention in infants) in India (SC)
  • 31 Jan 2014 Phase-II clinical trials in Mumps (prevention in infants) in India (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top